{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:51:41Z","timestamp":1778543501399,"version":"3.51.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate real-world changes in the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and corresponding molecular subtypes in primary and metastatic breast cancer, as well as their influencing factors and impact on prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed 436 paired lesion samples of primary and metastatic breast cancer treated between 2013 and 2023. Statistical evaluation was conducted to examine receptor discordance (ER, PR, HER2) and clinicopathological correlations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>Receptor discordance rates between primary and metastatic lesions were 25.1% for ER, 33.3% for PR, 32.8% for HER2, and 33.8% for molecular subtypes. PR showed the highest discordance, frequently transitioning from positive to negative. ER discordance predominantly involved the loss of low expression. HER2 discordance was highest in liver metastases (59.3%). Molecular subtype changes were most common in HR+\/HER2- tumors (42.6%). ER discordance correlated with neoadjuvant chemotherapy and endocrine therapy, while HER2 discordance was linked to targeted therapy and lung metastases. Loss of hormone receptor (HR) or HER2 expression was associated with poorer overall survival (OS) (HR: median OS 95 vs. 70 months, P\u00a0=\u00a00.0018; HER2: median OS 78 vs. 68 months, P\u00a0=\u00a00.025). Conversely, sustained or acquired HR\/HER2 positivity improved OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Heterogeneity in ER, PR, HER2, and molecular subtype expression significantly influences prognosis and treatment outcomes in metastatic breast cancer. Reassessment of receptor status in metastatic lesions is essential for optimizing individualized treatment strategies and improving patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1797175","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:14:19Z","timestamp":1776658459000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A decade of receptor discordance and phenotypic transitions in metastatic breast cancer: a single-center retrospective study of 363 cases"],"prefix":"10.3389","volume":"16","author":[{"given":"Sijie","family":"Chen","sequence":"first","affiliation":[{"name":"Cancer Center, the First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]},{"name":"Precision Medicine Center, the First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]},{"name":"Department of Medical Oncology, the First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Sun","sequence":"additional","affiliation":[{"name":"Cancer Center, the First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]},{"name":"Department of Medical Oncology, the First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[{"name":"Cancer Center, the First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]},{"name":"Department of Medical Oncology, the First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Cancer Center, the First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]},{"name":"Department of Medical Oncology, the First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[{"name":"Cancer Center, the First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]},{"name":"Precision Medicine Center, the First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]},{"name":"Department of Medical Oncology, the First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1245\/s10434-016-5631-3","article-title":"Evaluation of local and distant recurrence patterns in patients with triple-negative breast cancer according to age","volume":"24","author":"Radosa","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2020.05.032","article-title":"Receptor discordance and phenotype change in metastatic breast cancer","volume":"44","author":"Kao","year":"2021","journal-title":"Asian J Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0615-z","article-title":"Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution","volume":"33","author":"Chen","year":"2020","journal-title":"Mod Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00252-6","article-title":"Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort","volume":"7","author":"Grinda","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05746-8","article-title":"Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer","volume":"183","author":"Walter","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211012982","article-title":"Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer","volume":"13","author":"Zhao","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34365","article-title":"Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases","volume":"152","author":"Lin","year":"2023","journal-title":"Int J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.12596","article-title":"Molecular concordance between primary breast cancer and matched metastases","volume":"22","author":"Kr\u00f8ig\u00e5rd","year":"2016","journal-title":"Breast J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx273","article-title":"Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis","volume":"110","author":"Schrijver","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.05.003","article-title":"HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact","volume":"39","author":"Turner","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.10.004","article-title":"A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases","volume":"50","author":"Aurilio","year":"2014","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.017","article-title":"Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM)","volume":"75","author":"Duffy","year":"2017","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)\u2020","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx308","article-title":"De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017","volume":"28","author":"Curigliano","year":"2017","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1797175\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:14:20Z","timestamp":1776658460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1797175\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1797175"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1797175","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1797175"}}